$ 14.71
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Target Price
The average target price of AARD is 33 and suggests 121% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
